151 related articles for article (PubMed ID: 16485623)
1. Preventing sudden cardiac death in post myocardial infarction patients with left ventricular dysfunction.
Angerstein RL; Thompson B; Rasmussen MJ
J Cardiovasc Nurs; 2005; 20(6):397-404. PubMed ID: 16485623
[TBL] [Abstract][Full Text] [Related]
2. Medical therapy versus implantable cardioverter -defibrillator in preventing sudden cardiac death in patients with left ventricular systolic dysfunction and heart failure: a meta-analysis of > 35,000 patients.
Peck KY; Lim YZ; Hopper I; Krum H
Int J Cardiol; 2014 May; 173(2):197-203. PubMed ID: 24636548
[TBL] [Abstract][Full Text] [Related]
3. Can antiarrhythmic drugs survive survival trials?
Pratt CM; Waldo AL; Camm AJ
Am J Cardiol; 1998 Mar; 81(6A):24D-34D. PubMed ID: 9537220
[TBL] [Abstract][Full Text] [Related]
4. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II.
Klein H; Auricchio A; Reek S; Geller C
Am J Cardiol; 1999 Mar; 83(5B):91D-97D. PubMed ID: 10089848
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors affecting the all-cause death and sudden cardiac death rates of post myocardial infarction patients with low left ventricular ejection fraction.
Dai SM; Zhang S; Chen KP; Hua W; Wang FZ; Chen X
Chin Med J (Engl); 2009 Apr; 122(7):802-6. PubMed ID: 19493393
[TBL] [Abstract][Full Text] [Related]
6. Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: an evidence-based review.
Hilleman DE; Bauman AL
Pharmacotherapy; 2001 May; 21(5):556-75. PubMed ID: 11349745
[TBL] [Abstract][Full Text] [Related]
7. Post myocardial infarction, left ventricular dysfunction, and the expanding role of cardiac implantable electrical devices.
Naccarelli GV
Clin Cardiol; 2005 Nov; 28(11 Suppl 1):I51-7. PubMed ID: 16450813
[TBL] [Abstract][Full Text] [Related]
8. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
[TBL] [Abstract][Full Text] [Related]
9. Relation of body mass index to sudden cardiac death and the benefit of implantable cardioverter-defibrillator in patients with left ventricular dysfunction after healing of myocardial infarction.
Choy B; Hansen E; Moss AJ; McNitt S; Zareba W; Goldenberg I;
Am J Cardiol; 2010 Mar; 105(5):581-6. PubMed ID: 20185000
[TBL] [Abstract][Full Text] [Related]
10. MADIT II, the Multi-center Autonomic Defibrillator Implantation Trial II stopped early for mortality reduction, has ICD therapy earned its evidence-based credentials?
Coats AJ
Int J Cardiol; 2002 Jan; 82(1):1-5. PubMed ID: 11786150
[TBL] [Abstract][Full Text] [Related]
11. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. The Pediatric Electrophysiology Society.
Silka MJ; Kron J; Dunnigan A; Dick M
Circulation; 1993 Mar; 87(3):800-7. PubMed ID: 8443901
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms underlying the lack of effect of implantable cardioverter-defibrillator therapy on mortality in high-risk patients with recent myocardial infarction: insights from the Defibrillation in Acute Myocardial Infarction Trial (DINAMIT).
Dorian P; Hohnloser SH; Thorpe KE; Roberts RS; Kuck KH; Gent M; Connolly SJ
Circulation; 2010 Dec; 122(25):2645-52. PubMed ID: 21135366
[TBL] [Abstract][Full Text] [Related]
13. Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators: design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) study.
Bellocci F; Biasucci LM; Gensini GF; Padeletti L; Raviele A; Santini M; Giubilato G; Landolina M; Biondi-Zoccai G; Raciti G; Sassara M; Castro A; Kheir A; Crea F
J Cardiovasc Med (Hagerstown); 2007 Apr; 8(4):293-9. PubMed ID: 17413310
[TBL] [Abstract][Full Text] [Related]
14. Early echocardiographic deformation analysis for the prediction of sudden cardiac death and life-threatening arrhythmias after myocardial infarction.
Ersbøll M; Valeur N; Andersen MJ; Mogensen UM; Vinther M; Svendsen JH; Møller JE; Kisslo J; Velazquez EJ; Hassager C; Søgaard P; Køber L
JACC Cardiovasc Imaging; 2013 Aug; 6(8):851-60. PubMed ID: 23850252
[TBL] [Abstract][Full Text] [Related]
15. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction.
Sanders GD; Hlatky MA; Every NR; McDonald KM; Heidenreich PA; Parsons LS; Owens DK
Ann Intern Med; 2001 Nov; 135(10):870-83. PubMed ID: 11712877
[TBL] [Abstract][Full Text] [Related]
16. Drugs or implantable cardioverter-defibrillators in patients with poor left ventricular function?
Block M; Hammel D; Böcker D; Borggrefe M; Breithardt G
Am J Cardiol; 1996 Sep; 78(5A):62-8. PubMed ID: 8820838
[TBL] [Abstract][Full Text] [Related]
17. The clinical challenge of preventing sudden cardiac death immediately after acute ST-elevation myocardial infarction.
Manolis AS
Expert Rev Cardiovasc Ther; 2014 Dec; 12(12):1427-37. PubMed ID: 25382137
[TBL] [Abstract][Full Text] [Related]
18. Clinical criteria for predicting benefit of ICD/PM in post myocardial infarction patients: an AVID and CAST analysis.
Hallstrom AP; Wyse DG; McAnulty J; ;
J Interv Card Electrophysiol; 2008 Dec; 23(3):159-66. PubMed ID: 18810620
[TBL] [Abstract][Full Text] [Related]
19. Traditional heart failure medications and sudden cardiac death prevention: a review.
Al Chekakie MO
J Cardiovasc Pharmacol Ther; 2013 Sep; 18(5):412-26. PubMed ID: 23766358
[TBL] [Abstract][Full Text] [Related]
20. Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction.
Epstein AE; Abraham WT; Bianco NR; Kern KB; Mirro M; Rao SV; Rhee EK; Solomon SD; Szymkiewicz SJ
J Am Coll Cardiol; 2013 Nov; 62(21):2000-2007. PubMed ID: 23916930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
